Clinical trials for hidradenitis suppurativa
Explore current HS research studies, learn what questions to ask, and find opportunities that may be a fit for you or your family.
Find current HS clinical trial opportunities
HS research is constantly evolving. HS Connect brings together current clinical trial opportunities to make it easier for patients and caregivers to see what research is happening and where studies are recruiting.
U.S. Clinical Trials
Browse currently listed studies recruiting participants in the United States.
View U.S. Trials ↓International Clinical Trials
Explore HS research opportunities taking place outside the United States.
View International Trials ↓What is a clinical trial?
Clinical trials are research studies that help doctors and researchers learn more about conditions like HS, test potential treatments, and understand how care can improve over time.
Learn
Review the study purpose, age range, location, visits, and what participation involves.
Screen
The study team asks questions to see whether you may meet the study requirements.
Decide
You can ask questions, review risks and benefits, and choose whether participation feels right.
Participate
If eligible, you follow the study plan with guidance from the research team.
Clinical trials are a choice.
Being interested in a trial does not mean you have to enroll. Asking questions is part of the process. You should feel informed, respected, and supported before making any decision.
U.S. clinical trial opportunities
Browse HS clinical trials currently listed for U.S. participants. These are pulled from your Clinical Trial posts using the U.S. location filter.
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 18 Years
Status: Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
AGE: 18 Years – 100 Years
Status: Recruiting
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
AGE: 18 Years – 65 Years
Status: Recruiting
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
AGE: 12 Years
Status: Recruiting
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
AGE: 18 Years
Status: Recruiting
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 12 Years – 17 Years
Status: Recruiting
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
AGE: 18 Years – 79 Years
Moderate-to-Severe
Status: Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (BE CARING)
AGE: 18+
ALL
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Radiotherapy for Refractory Hidradenitis Suppurativa (RADIANTSUPPoRT)
AGE: 18+
II or III
Status: Recruiting
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (STOP-LTR)
AGE: 18+
ALL
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
AGE: 12+
I, II, III
Status: Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AGE: 18-75
SEVERITY: Moderate to severe
Status: Recruiting
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
AGE: AGE: 18+
SEVERITY: Mild to moderate
Status: Recruiting
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: Recruiting
Clinical and Biological Characteristics of Hidradenitis Suppurativa
AGE: AGE: 13+
HURLEY STAGE: All
Status: Recruiting
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
AGE: AGES: 10+
HURLEY STAGE: All
Status: Recruiting
Botulinum Toxin Therapy in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: Recruiting
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: Recruiting
Myriad™ Augmented Soft Tissue Reconstruction Registry
AGE: AGE: 18+
HURLEY STAGE: All
Status: Recruiting
The Ohio State University Dermatology Biorepository
AGE: AGE: 7+
HURLEY STAGE: All
Status: Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: Recruiting
Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: Recruiting
International clinical trial opportunities
Explore currently listed HS clinical trials taking place outside the United States. New international studies are added as opportunities become available.
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 18 Years
Status: Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
AGE: 18 Years – 100 Years
Status: Recruiting
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
AGE: 18 Years
Status: Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
AGE: 18 Years – 100 Years
Status: Recruiting
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
AGE: 18 Years – 59 Years
Status: Recruiting
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 12 Years – 17 Years
Status: Recruiting
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
AGE: 18 Years – 99 Years
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
AGE: 18+
ALL
Status: Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (BE CARING)
AGE: 18+
ALL
Status: Recruiting
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa (MEASUREAAVitHS)
AGE: 12+
Moderate to Severe
Status: Recruiting
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
AGE: 18+
ALL
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
AGE: 18+
Moderate to Severe
Status: Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (STOP-LTR)
AGE: 18+
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Placebo vs. Nocebo Effect
Learn the difference between the placebo and nocebo effects, how they influence HS clinical trials and treatment experiences, and why a positive mindset may help you get the most from your care.
Placebo vs. Nocebo Effect
Learn the difference between the placebo and nocebo effects, how they influence HS clinical trials and treatment experiences, and why a positive mindset may help you get the most from your care.
Questions to ask before joining a clinical trial
You deserve clear answers before deciding whether a study is right for you.
Study basics
What is the study testing? How long does it last? How many visits are required?
Eligibility
What age, diagnosis, severity, medication, or location requirements apply?
Costs and compensation
Are study visits, travel, parking, or time compensated? Are there any costs?
Risks and benefits
What are the possible side effects, risks, and expected monitoring steps?
Placebo or active treatment
Is there a placebo or vehicle group? Will everyone receive the study treatment?
Your rights
Can you stop participating? Who do you contact with concerns or questions?